COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders– updated guidance (NG167)

NICE has updated recommendation 4.9 on biological treatments. This now states “Assess whether patients having intravenous treatment can be switched to the same treatment in subcutaneous form. If this is not possible, discuss with the patient an alternative subcutaneous treatment”


National Institute for Health and Care Excellence